new glp 1 drugs in development Market Overview: GLP-1 Agonists and the Obesity Market | Blog GLP-1 Drugs: 6 Things We've

If you switch immediately without a washout, weight typically continues downward or holds steady

Patients should also report any side effects they experience , particularly severe, persistent abdominal pain (with or without vomiting) which could suggest pancreatitis or gallbladder disease and requires urgent medical review

The drug never fixed the dysregulated systems

Safety profiling of GLP-1 therapy Studies have found that GLP-1 agonists are associated with increased risk of gastrointestinal adverse events spanning from nausea and vomiting to pancreatitis and kidney dysfunction

doi: 10.1016/j.nlm.2010.02.002 [DOI] [PMC free article] [PubMed] [Google Scholar] 56